Shingles Vaccine Linked to 24% Lower Risk of Dementia in Major New Study

The search for a dementia preventative has cost billions of dollars and yielded decades of frustration. But a growing body of evidence suggests that a powerful tool against cognitive decline might already be sitting in thousands of pharmacy refrigerators across the country.

According to a major new study published in the Annals of Internal Medicine, older adults who received the modern shingles vaccine had a 24 percent lower risk of being diagnosed with dementia over a four-year period compared to their unvaccinated peers.[1][5]

The findings, led by researchers at Brown University's School of Public Health, represent one of the most significant real-world signals yet that vaccination could play a direct role in protecting brain health.[4]

"This translates to about one in 17 dementia cases potentially being prevented," said Dr. Kaley Hayes, the study's lead author and an associate director of pharmacoepidemiology at Brown.[3][4]

The research utilized a "target trial emulation" model, analyzing the Medicare and electronic health records of more than 500,000 adults aged 66 and older.[3][5]

All of the participants had been admitted to skilled nursing facilities for short- or long-term care between 2017 and 2022. By focusing on this specific demographic, the researchers were able to track a population that is at elevated risk for both shingles and dementia.[2][5]

The results were stark. Among the unvaccinated group, 24.6 percent developed dementia within four years. For those who received at least one dose of the recombinant zoster vaccine—marketed as Shingrix—that number fell to 18.8 percent.[3][4]

This absolute risk reduction of 5.8 percentage points is massive in the context of neurodegenerative disease, where traditional pharmaceutical interventions often yield only marginal delays in cognitive decline.[7]

But why would a vaccine designed to prevent a painful skin rash have any effect on the brain? Scientists are currently debating three primary mechanisms.[7]

The first theory centers on the varicella-zoster virus itself. After a childhood chickenpox infection, the virus lies dormant in the nervous system for life. When it reactivates as shingles in older age, it can cause severe neuroinflammation and increase the risk of stroke—both of which are known catalysts for dementia.[3][4]

By preventing the virus from reactivating, the vaccine may simply be shielding the brain from the cascading vascular and inflammatory damage that shingles inflicts.[3]

The second theory is more intriguing: the benefit might come from the vaccine's ingredients rather than the virus it targets. Shingrix contains a specific adjuvant called AS01, a compound designed to provoke a highly robust immune response.[2]

Some immunologists hypothesize that this intense immune activation essentially "wakes up" the body's cellular cleanup crews, prompting them to clear out the toxic amyloid plaques and tau tangles associated with Alzheimer's disease.[2][7]

This theory gained traction last year when researchers noticed that the new RSV vaccine, Arexvy—which uses the exact same AS01 adjuvant—also appeared to correlate with a lower incidence of dementia.[2]

The Brown University study builds on a foundation of earlier research. A landmark 2025 study out of Wales, analyzed by Stanford Medicine, found that the older, live-attenuated shingles vaccine (Zostavax) reduced dementia risk by 20 percent over seven years.[6]

The new data confirms that the modern recombinant vaccine, which replaced Zostavax in the U.S. in 2017, is not only more effective at preventing shingles but also offers superior neuroprotective benefits.[3][4]

Despite the compelling data, clinical skeptics caution against declaring the vaccine a definitive cure-all just yet. The primary concern in observational studies is "healthy vaccinee bias"—the reality that people who proactively get vaccinated tend to have better overall health behaviors, which might independently lower their dementia risk.[2]

While the Brown researchers rigorously adjusted their data to account for baseline health differences, proving a direct causal link will ultimately require randomized controlled trials specifically designed to measure cognitive outcomes.[4]

Nevertheless, the implications for public health are profound. Dementia currently affects more than 55 million people worldwide, a number expected to skyrocket as the global population ages.[6]

If a widely accessible, FDA-approved vaccine can safely eliminate nearly a quarter of new dementia cases in high-risk populations, it could fundamentally alter the trajectory of global aging and cognitive care.[7]